SCHEMBL6835136

SCHEMBL6835136

COc1ccc(C(=O)NC(C)O)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 3/20 0.61
CA2 P00918 3/20 0.61
PLK1 P53350 1/20 0.61
TAS1R3 Q7RTX0 1/20 0.61
TAS1R1 Q7RTX1 1/20 0.61
NPC1 O15118 3/20 0.58
RAB9A P51151 3/20 0.58
TP53 P04637 2/20 0.58
SMN1; SMN2 Q16637 2/20 0.58
ALOX15 P16050 1/20 0.58
ALDH1A1 P00352 5/20 0.55
MEN1 O00255 3/20 0.55
KMT2A Q03164 3/20 0.55
MAPT P10636 2/20 0.55
CYP3A4 P08684 3/20 0.55
CYP1A2 P05177 2/20 0.55
CYP2C9 P11712 2/20 0.55
CYP2C19 P33261 2/20 0.55
F10 P00742 1/20 0.54
CES2 O00748 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8330051 0.89 CA1 (0.66) CA1CA2PLK1TAS1R3TAS1R1
SCHEMBL27817512 0.86 HPGD (0.52) CA1CA2NPC1RAB9ASMN1; SMN2
SCHEMBL23440083 0.84 TAS1R3 (0.59) CA1CA2PLK1TAS1R3TAS1R1
SCHEMBL13753434 0.84 TAS1R3 (0.59) CA1CA2PLK1TAS1R3TAS1R1
SCHEMBL28354065 0.82 TAS1R3 (0.70) CA1CA2PLK1TAS1R3TAS1R1
SCHEMBL5637591 0.82 CA2 (0.58) CA1CA2PLK1TAS1R3TAS1R1
SCHEMBL9829827 0.82 CA2 (0.58) CA1CA2PLK1TAS1R3TAS1R1
SCHEMBL5639560 0.82 TAS1R3 (0.58) CA1CA2PLK1TAS1R3TAS1R1
SCHEMBL21952784 0.82 TAS1R3 (0.58) CA1CA2PLK1TAS1R3TAS1R1
SCHEMBL8281658 0.82 TAS1R3 (0.54) CA1CA2PLK1TAS1R3TAS1R1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040082774-A1 Novel phosphate and thiophosphate protecting groups ISIS PHARMACEUTICALS, INC. 2004-04-29 US disclosed
US-6610837-B1 Preparation of an oligonucleotide compound of given formula by reacting with given compounds, followed by oxidation or sulfurization ISIS PHARMACEUTICALS, INC. 2003-08-26 US disclosed
WO-2000055179-A1 NOVEL PHOSPHATE AND THIOPHOSPHATE PROTECTING GROUPS ISIS PHARMACEUTICALS, INC. (US) 2000-09-21 WO disclosed
US-6121437-A SYNTHESIS OF OLIGONUCLEOTIDES USING OLIGONUCLEOTIDES OR NUCLEOTIDES WITH PROTECTED INTERNUCLEOSIDIC PHOSPHORUS FUNCTIONALITIES WHICH CAN BE REMOVED UNDER MILD CONDITIONS AND PRODUCE NONTOXIC BY-PRODUCTS ISIS PHARMACEUTICALS, INC. (US) 2000-09-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040082774-A1 Novel phosphate and thiophosphate protecting groups TYMP, MTAP, PPIP5K2 CA1 2225/4885CA2 1649/4885PLK1 655/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.